ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 572,81
-0,78%
Dow Jones
40 211,72
0,53%
DAX
18 504,23
-0,52%
Brent Oil
83,275
-1,26%
Bitcoin
63 663,31
-1,83%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Summit Therapeutics Inc (SMMT)

  7. Summit Therapeutics Inc (SMMT) Actualités

SMMT

Summit Therapeutics (SMMT)

Summit Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:SMMT
DateHeureSourceTitreSymboleSociété
23/01/202312h04Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3/a)NASDAQ:SMMTSummit Therapeutics Inc
20/01/202323h16Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SMMTSummit Therapeutics Inc
20/01/202314h00Business WireSummit Therapeutics Closes Deal with Akeso Inc. to In-License Breakthrough Innovative Bispecific AntibodyNASDAQ:SMMTSummit Therapeutics Inc
05/01/202322h22Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SMMTSummit Therapeutics Inc
05/01/202313h00Business WireSummit Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceNASDAQ:SMMTSummit Therapeutics Inc
21/12/202222h52Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:SMMTSummit Therapeutics Inc
13/12/202222h07Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:SMMTSummit Therapeutics Inc
09/12/202223h25Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:SMMTSummit Therapeutics Inc
06/12/202222h46TipRanksSummit Therapeutics Explodes Up on Licensing DealNASDAQ:SMMTSummit Therapeutics Inc
06/12/202213h30GlobeNewswire Inc.Summit Therapeutics Partners with Akeso Inc. in Deal for Up to $5 Billion to In-License Breakthrough Innovative Bispecific AntibodyNASDAQ:SMMTSummit Therapeutics Inc
17/11/202222h25Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:SMMTSummit Therapeutics Inc
17/11/202222h15GlobeNewswire Inc.Summit Therapeutics Appoints Experienced Clinical Leader Dr. Alessandra Cesano to its Board of DirectorsNASDAQ:SMMTSummit Therapeutics Inc
09/11/202222h25Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:SMMTSummit Therapeutics Inc
09/11/202214h30GlobeNewswire Inc.Summit Therapeutics Inc. Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2022NASDAQ:SMMTSummit Therapeutics Inc
20/10/202223h15GlobeNewswire Inc.Summit Therapeutics Presents Ri-CoDIFy Trial Results for Microbiome-Sparing Ridinilazole at IDWeek 2022NASDAQ:SMMTSummit Therapeutics Inc
13/10/202214h00GlobeNewswire Inc.Summit Therapeutics to Present Ri-CoDIFy Trial Results for Microbiome-Sparing Ridinilazole at IDWeek 2022NASDAQ:SMMTSummit Therapeutics Inc
03/10/202222h36GlobeNewswire Inc.Summit Therapeutics Appoints Dr. Robert Booth, Renowned Executive and Scientific Leader, to its Board of DirectorsNASDAQ:SMMTSummit Therapeutics Inc
11/08/202214h00GlobeNewswire Inc.Summit Therapeutics Inc Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2022NASDAQ:SMMTSummit Therapeutics Inc
09/08/202219h37GlobeNewswire Inc.Summit Therapeutics Closes Fully-Subscribed $100 Million Rights OfferingNASDAQ:SMMTSummit Therapeutics Inc
02/08/202215h25GlobeNewswire Inc.Summit Therapeutics’ Rights Offering Nearing Expiration DateNASDAQ:SMMTSummit Therapeutics Inc
26/07/202222h15GlobeNewswire Inc.Summit Therapeutics Appoints Dr. Maky Zanganeh as Co-CEO & PresidentNASDAQ:SMMTSummit Therapeutics Inc
18/07/202222h05GlobeNewswire Inc.Summit Therapeutics Announces Commencement of $100 Million Rights OfferingNASDAQ:SMMTSummit Therapeutics Inc
18/07/202221h50Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(4) (424b4)NASDAQ:SMMTSummit Therapeutics Inc
14/07/202214h30GlobeNewswire Inc.Summit Therapeutics Provides Update on RidinilazoleNASDAQ:SMMTSummit Therapeutics Inc
22/06/202222h30GlobeNewswire Inc.Summit Therapeutics Announces $100 Million Rights OfferingNASDAQ:SMMTSummit Therapeutics Inc
03/06/202222h32Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:SMMTSummit Therapeutics Inc
03/06/202214h30GlobeNewswire Inc.Summit Therapeutics’ Upcoming Annual Shareholders’ MeetingNASDAQ:SMMTSummit Therapeutics Inc
01/06/202214h30GlobeNewswire Inc.Summit Therapeutics Appoints Ankur Dhingra as Chief Financial OfficerNASDAQ:SMMTSummit Therapeutics Inc
11/05/202222h30GlobeNewswire Inc.Summit Therapeutics Inc Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2022NASDAQ:SMMTSummit Therapeutics Inc
14/04/202222h13Edgar (US Regulatory)Confidential Treatment Order (ct Order)NASDAQ:SMMTSummit Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:SMMT

Dernières Valeurs Consultées

NASDAQ
AAPL
Apple
EU
ORA
Orange
NYSE
MCD
McDonalds
EU
CS
Axa
EU
LR
Legrand
EU
PX1
CAC 40
NYSE
KO
Coca Cola
EU
RI
Pernod Ricard
EU
PX4
SBF 120
EU
AF
Air FranceKLM
COIN
BTCUSD
Bitcoin
EU
ACA
Credit Agricole
NYSE
NKE
Nike
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés